Cellular and molecular approaches to motor neuron therapy in amyotrophic lateral sclerosis and spinal muscular atrophy

Neuroscience Letters

Volumn 527, Issue 2, 2012, Pages 78-84

  O'Connor, Deirdre M ^a   Boulis, Nicholas M ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Amyotrophic lateral sclerosis; Clinical trials; Gene therapy; Spinal muscular atrophy; Stem cells

Indexed keywords

ADENOVIRUS VECTOR; HERPES SIMPLEX VIRUS VECTOR; LENTIVIRUS VECTOR; PARVOVIRUS VECTOR; UNCLASSIFIED DRUG; VIRUS VECTOR;

AMYOTROPHIC LATERAL SCLEROSIS; CELL THERAPY; DRUG DELIVERY SYSTEM; GENE EXPRESSION; GENE THERAPY; HUMAN; MESENCHYMAL STEM CELL; MOTONEURON; NEURAL STEM CELL; NONHUMAN; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REVIEW; SPINAL MUSCULAR ATROPHY; STEM CELL TRANSPLANTATION; TRANSGENE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; CLINICAL TRIALS AS TOPIC; GENETIC THERAPY; GENETIC VECTORS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MESENCHYMAL STEM CELL TRANSPLANTATION; MOTOR NEURONS; MUSCULAR ATROPHY, SPINAL; NEURAL STEM CELLS; STEM CELL TRANSPLANTATION;

EID: 84866745607     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2012.04.079     Document Type: Review

References (63)

1. Aboody K., Capela A., Niazi N., Stern J.H., Temple S. Translating stem cell studies to the clinic for CNS repair: current state of the art and the need for a Rosetta Stone. Neuron 2011, 70:597-613.
2. Azzouz M., Le T., Ralph G.S., Walmsley L., Monani U.R., Lee D.C., Wilkes F., Mitrophanous K.A., Kingsman S.M., Burghes A.H., Mazarakis N.D. Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy. Journal of Clinical Investigation 2004, 114:1726-1731.
3. Azzouz M., Ralph G.S., Storkebaum E., Walmsley L.E., Mitrophanous K.A., Kingsman S.M., Carmeliet P., Mazarakis N.D. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 2004, 429:413-417.
4. Bevan A.K., Duque S., Foust K.D., Morales P.R., Braun L., Schmelzer L., Chan C.M., McCrate M., Chicoine L.G., Coley B.D., Porensky P.N., Kolb S.J., Mendell J.R., Burghes A.H., Kaspar B.K. Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders. Molecular Therapy: The Journal of the American Society of Gene Therapy 2011, 19:1971-1980.
5. Bigini P., Veglianese P., Andriolo G., Cova L., Grignaschi G., Caron I., Daleno C., Barbera S., Ottolina A., Calzarossa C., Lazzari L., Mennini T., Bendotti C., Silani V. Intracerebroventricular administration of human umbilical cord blood cells delays disease progression in two murine models of motor neuron degeneration. Rejuvenation Research 2011, 14:623-639.
6. Boulis N.M., Noordmans A.J., Song D.K., Imperiale M.J., Rubin A., Leone P., During M., Feldman E.L. Adeno-associated viral vector gene expression in the adult rat spinal cord following remote vector delivery. Neurobiology of Disease 2003, 14:535-541.
7. Boulis N.M., Turner D.E., Dice J.A., Bhatia V., Feldman E.L. Characterization of adenoviral gene expression in spinal cord after remote vector delivery. Neurosurgery 1999, 45:131-137. discussion 137-138.
8. Boutin S., Monteilhet V., Veron P., Leborgne C., Benveniste O., Montus M.F., Masurier C. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Human Gene Therapy 2010, 21:704-712.
9. Chow C.Y., Landers J.E., Bergren S.K., Sapp P.C., Grant A.E., Jones J.M., Everett L., Lenk G.M., McKenna-Yasek D.M., Weisman L.S., Figlewicz D., Brown R.H., Meisler M.H. Deleterious variants of FIG4, a phosphoinositide phosphatase, in patients with ALS. American Journal of Human Genetics 2009, 84:85-88.
10. Corti S., Nizzardo M., Nardini M., Donadoni C., Salani S., Ronchi D., Saladino F., Bordoni A., Fortunato F., Del Bo R., Papadimitriou D., Locatelli F., Menozzi G., Strazzer S., Bresolin N., Comi G.P. Neural stem cell transplantation can ameliorate the phenotype of a mouse model of spinal muscular atrophy. Journal of Clinical Investigation 2008, 118:3316-3330.
11. Corti S., Nizzardo M., Nardini M., Donadoni C., Salani S., Simone C., Falcone M., Riboldi G., Govoni A., Bresolin N., Comi G.P. Systemic transplantation of c-kit+ cells exerts a therapeutic effect in a model of amyotrophic lateral sclerosis. Human Molecular Genetics 2010, 19:3782-3796.
12. Dimos J.T., Rodolfa K.T., Niakan K.K., Weisenthal L.M., Mitsumoto H., Chung W., Croft G.F., Saphier G., Leibel R., Goland R., Wichterle H., Henderson C.E., Eggan K. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 2008, 321:1218-1221.
13. Dodge J.C., Haidet A.M., Yang W., Passini M.A., Hester M., Clarke J., Roskelley E.M., Treleaven C.M., Rizo L., Martin H., Kim S.H., Kaspar R., Taksir T.V., Griffiths D.A., Cheng S.H., Shihabuddin L.S., Kaspar B.K. Delivery of AAV-IGF-1 to the CNS extends survival in ALS mice through modification of aberrant glial cell activity. Molecular Therapy: The Journal of the American Society of Gene Therapy 2008, 16:1056-1064.
14. Ebert A.D., Svendsen C.N. Human stem cells and drug screening: opportunities and challenges. Nature Reviews Drug Discovery 2010, 9:367-372.
15. Federici T., Boulis N. Gene-based treatment of motor neuron diseases. Muscle and Nerve 2006, 33:302-323.
16. Federici T., Kutner R., Zhang X.Y., Kuroda H., Tordo N., Boulis N.M., Reiser J. Comparative analysis of HIV-1-based lentiviral vectors bearing lyssavirus glycoproteins for neuronal gene transfer. Genet Vaccines Therapy 2009, 7:1.
17. Federici T., Liu J., Teng Q., Garrity-Moses M., Yang J., Boulis N. In vivo spinal cord uptake and neuronal binding properties of Tet1: A potential means for enhanced spinal cord AAV delivery. Molecular Therapy 2005, 11:S332.
18. Federici T., Taub J.S., Gray S.J., Foti S., Grieger J.C., Handy C.R., Donnelly E.M., Samulski R.J., Boulis N.M. Robust motor neuron transduction following intrathecal delivery of AAV9.GFP to pigs. ASGCT 14th Annual Meeting, vol. 19 2011, S250. Nature Publishing Group, Seattle, WA.
19. Fink D.J., Sternberg L.R., Weber P.C., Mata M., Goins W.F., Glorioso J.C. In vivo expression of beta-galactosidase in hippocampal neurons by HSV-mediated gene transfer. Human Gene Therapy 1992, 3:11-19.
20. Forostyak S., Jendelova P., Kapcalova M., Arboleda D., Sykova E. Mesenchymal stromal cells prolong the lifespan in a rat model of amyotrophic lateral sclerosis. Cytotherapy 2011, 13:1036-1046.
21. Foust K.D., Nurre E., Montgomery C.L., Hernandez A., Chan C.M., Kaspar B.K. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nature Biotechnology 2009, 27:59-65.
22. Foust K.D., Wang X., McGovern V.L., Braun L., Bevan A.K., Haidet A.M., Le T.T., Morales P.R., Rich M.M., Burghes A.H., Kaspar B.K. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nature Biotechnology 2010, 28:271-274.
23. Franz C.K., Federici T., Yang J., Backus C., Oh S.S., Teng Q., Carlton E., Bishop K.M., Gasmi M., Bartus R.T., Feldman E.L., Boulis N.M. Intraspinal cord delivery of IGF-I mediated by adeno-associated virus 2 is neuroprotective in a rat model of familial ALS. Neurobiology of Disease 2009, 33:473-481.
24. Glass J.D., Boulis N.M., Johe K., Rutkove S.B., Federici T., Polak M., Kelly C., Feldman E.L. Lumbar intraspinal injection of neural stem cells in patients with ALS: Results of a phase I trial in 12 patients. Stem Cells 2012, 30:1144-1151.
25. Gray S.J., Matagne V., Bachaboina L., Yadav S., Ojeda S.R., Samulski R.J. Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Molecular Therpy 2011, 19:1058-1069.
26. Greenway M.J., Andersen P.M., Russ C., Ennis S., Cashman S., Donaghy C., Patterson V., Swingler R., Kieran D., Prehn J., Morrison K.E., Green A., Acharya K.R., Brown R.H., Hardiman O. ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis. Nature Genetics 2006, 38:411-413.
27. Hacein-Bey-Abina S., Garrigue A., Wang G.P., Soulier J., Lim A., Morillon E., Clappier E., Caccavelli L., Delabesse E., Beldjord K., Asnafi V., MacIntyre E., Dal Cortivo L., Radford I., Brousse N., Sigaux F., Moshous D., Hauer J., Borkhardt A., Belohradsky B.H., Wintergerst U., Velez M.C., Leiva L., Sorensen R., Wulffraat N., Blanche S., Bushman F.D., Fischer A., Cavazzana-Calvo M. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. Journal of Clinical Investigation 2008, 118:3132-3142.
28. Heath C.A. Cells for tissue engineering. Trends in Biotechnology 2000, 18:17-19.
29. Henriques A., Pitzer C., Dittgen T., Klugmann M., Dupuis L., Schneider A. CNS-targeted viral delivery of G-CSF in an animal model for ALS: improved efficacy and preservation of the neuromuscular unit. Molecular Therapy: The Journal of the American Society of Gene Therapy 2011, 19:284-292.
30. Howland D.S., Liu J., She Y., Goad B., Maragakis N.J., Kim B., Erickson J., Kulik J., DeVito L., Psaltis G., DeGennaro L.J., Cleveland D.W., Rothstein J.D. Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proceedings of the National Academy of Sciences of the United States of America 2002, 99:1604-1609.
31. Karussis D., Karageorgiou C., Vaknin-Dembinsky A., Gowda-Kurkalli B., Gomori J.M., Kassis I., Bulte J.W., Petrou P., Ben-Hur T., Abramsky O., Slavin S. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Archives of Neurology 2010, 67:1187-1194.
32. Kaspar B.K., Llado J., Sherkat N., Rothstein J.D., Gage F.H. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 2003, 301:839-842.
33. Knippenberg S., Thau N., Schwabe K., Dengler R., Schambach A., Hass R., Petri S. Intraspinal injection of human umbilical cord blood-derived cells is neuroprotective in a transgenic mouse model of amyotrophic lateral sclerosis. Neurodegenerative Diseases 2012, 9:107-120.
34. Kwiatkowski T.J., Bosco D.A., Leclerc A.L., Tamrazian E., Vanderburg C.R., Russ C., Davis A., Gilchrist J., Kasarskis E.J., Munsat T., Valdmanis P., Rouleau G.A., Hosler B.A., Cortelli P., de Jong P.J., Yoshinaga Y., Haines J.L., Pericak-Vance M.A., Yan J., Ticozzi N., Siddique T., McKenna-Yasek D., Sapp P.C., Horvitz H.R., Landers J.E., Brown R.H. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 2009, 323:1205-1208.
35. Lefebvre S., Burglen L., Reboullet S., Clermont O., Burlet P., Viollet L., Benichou B., Cruaud C., Millasseau P., Zeviani M., LePaslier D., Frezal J., Cohen D., Weissenbach J., Munnich A., Melkio J. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995, 80:155-165.
36. Lesbordes J.C., Cifuentes-Diaz C., Miroglio A., Joshi V., Bordet T., Kahn A., Melki J. Therapeutic benefits of cardiotrophin-1 gene transfer in a mouse model of spinal muscular atrophy. Human Molecular Genetics 2003, 12:1233-1239.
37. Lilley C.E., Groutsi F., Han Z., Palmer J.A., Anderson P.N., Latchman D.S., Coffin R.S. Multiple immediate-early gene-deficient herpes simplex virus vectors allowing efficient gene delivery to neurons in culture and widespread gene delivery to the central nervous system in vivo. Journal of Virology 2001, 75:4343-4356.
38. Lunn J.S., Sakowski S.A., Federici T., Glass J.D., Boulis N.M., Feldman E.L. Stem cell technology for the study and treatment of motor neuron diseases. Regenerative Medicine 2011, 6:201-213.
39. Mazarakis N.D., Azzouz M., Rohll J.B., Ellard F.M., Wilkes F.J., Olsen A.L., Carter E.E., Barber R.D., Baban D.F., Kingsman S.M., Kingsman A.J., O'Malley K., Mitrophanous K.A. Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery. Human Molecular Genetics 2001, 10:2109-2121.
40. Park S., Kim H.T., Yun S., Kim I.S., Lee J., Lee I.S., Park K.I. Growth factor-expressing human neural progenitor cell grafts protect motor neurons but do not ameliorate motor performance and survival in ALS mice. Experimental and Molecular Medicine 2009, 41:487-500.
41. Parker M.A., Anderson J.K., Corliss D.A., Abraria V.E., Sidman R.L., Park K.I., Teng Y.D., Cotanche D.A., Snyder E.Y. Expression profile of an operationally-defined neural stem cell clone. Experimental Neurology 2005, 194:320-332.
42. Passini M.A., Bu J., Roskelley E.M., Richards A.M., Sardi S.P., O'Riordan C.R., Klinger K.W., Shihabuddin L.S., Cheng S.H. CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy. Journal of Clinical Investigation 2010, 120:1253-1264.
43. Pastor D., Viso-Leon M.C., Jones J., Jaramillo-Merchan J., Toledo-Aral J.J., Moraleda J.M., Martinez S. Comparative Effects between Bone Marrow and Mesenchymal Stem Cell Transplantation in GDNF Expression and Motor Function Recovery in a Motorneuron Degenerative Mouse Model 2011, Stem Cell Rev.
44. Perez M.C., Hunt S.P., Coffin R.S., Palmer J.A. Comparative analysis of genomic HSV vectors for gene delivery to motor neurons following peripheral inoculation in vivo. Gene Therapy 2004, 11:1023-1032.
45. Ralph G.S., Radcliffe P.A., Day D.M., Carthy J.M., Leroux M.A., Lee D.C., Wong L.F., Bilsland L.G., Greensmith L., Kingsman S.M., Mitrophanous K.A., Mazarakis N.D., Azzouz M. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nature Medicine 2005, 11:429-433.
46. Raore B., Federici T., Taub J., Wu M.C., Riley J., Franz C.K., Kliem M.A., Snyder B., Feldman E.L., Johe K., Boulis N.M. Cervical multilevel intraspinal stem cell therapy: assessment of surgical risks in Gottingen minipigs. Spine (Phila Pa 1976) 2011, 36:E164-E171.
47. Raore B., Federici T., Taub J., Wu M.C., Riley J., Franz C.K., Kliem M.A., Snyder B., Feldman E.L., Johe K., Boulis N.M. Cervical multilevel intraspinal stem cell therapy: assessment of surgical risks in Gottingen minipigs. Spine 2011, 36:E164-E171.
48. Raper S.E., Chirmule N., Lee F.S., Wivel N.A., Bagg A., Gao G.P., Wilson J.M., Batshaw M.L. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Molecular Genetics and Metabolism 2003, 80:148-158.
49. Riley J., Federici T., Park J., Suzuki M., Franz C., Tork C., McHugh J., Teng Q., Svendsen C., Boulis N. Cervical Spinal Cord Therapeutic Delivery: Preclinical Safety Validation of a Stabilized Microinjection Platform. Neurosurgery 2009, 65:754-762.
50. Samaranch L., Salegio E.A., San Sebastian W., Kells A.P., Foust K.D., Bringas J.R., Lamarre C., Forsayeth J., Kaspar B.K., Bankiewicz K.S. Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates. Human Gene Therapy 2012, 23:382-389.
51. Snyder B.R., Gray S.J., Quach E.T., Huang J.W., Leung C.H., Samulski R.J., Boulis N.M., Federici T. Comparison of Adeno-Associated Viral Vector Serotypes for Spinal Cord and Motor Neuron Gene Delivery 2011, Hum Gene Ther.
52. Sreedharan J., Blair I.P., Tripathi V.B., Hu X., Vance C., Rogelj B., Ackerley S., Durnall J.C., Williams K.L., Buratti E., Baralle F., de Belleroche J., Mitchell J.D., Leigh P.N., Al-Chalabi A., Miller C.C., Nicholson G., Shaw C.E. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 2008, 319:1668-1672.
53. St George J.A. Gene therapy progress and prospects: adenoviral vectors. Gene Therapy 2003, 10:1135-1141.
54. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131:861-872.
55. Tanase D., Garrity-Moses M., Liu J., Teng Q., Mazarakis N., Boulis N. Techniques for remote cervical spinal cord delivery of neurotherapeutic RabG-EIAV encoded genes. Molecular Therapy 2003, 7:S97.
56. Tsai L.K., Chen Y.C., Cheng W.C., Ting C.H., Dodge J.C., Hwu W.L., Cheng S.H., Passini M.A. IGF-1 delivery to CNS attenuates motor neuron cell death but does not improve motor function in type III SMA mice. Neurobiology of Disease 2012, 45:272-279.
57. Uccelli A., Moretta L., Pistoia V. Immunoregulatory function of mesenchymal stem cells. European Journal of Immunology 2006, 36:2566-2573.
58. Usvald D., Vodicka P., Hlucilova J., Prochazka R., Motlik J., Kuchorova K., Johe K., Marsala S., Scadeng M., Kakinohana O., Navarro R., Santa M., Hefferan M.P., Yaksh T.L., Marsala M. Analysis of dosing regimen and reproducibility of intraspinal grafting of human spinal stem cells in immunosuppressed minipigs. Cell Transplantation 2010, 19:1103-1122.
59. Vance C., Rogelj B., Hortobagyi T., De Vos K.J., Nishimura A.L., Sreedharan J., Hu X., Smith B., Ruddy D., Wright P., Ganesalingam J., Williams K.L., Tripathi V., Al-Saraj S., Al-Chalabi A., Leigh P.N., Blair I.P., Nicholson G., de Belleroche J., Gallo J.M., Miller C.C., Shaw C.E. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 2009, 323:1208-1211.
60. Vercelli A., Mereuta O.M., Garbossa D., Muraca G., Mareschi K., Rustichelli D., Ferrero I., Mazzini L., Madon E., Fagioli F. Human mesenchymal stem cell transplantation extends survival, improves motor performance and decreases neuroinflammation in mouse model of amyotrophic lateral sclerosis. Neurobiology of Disease 2008, 31:395-405.
61. Wang L.J., Lu Y.Y., Muramatsu S., Ikeguchi K., Fujimoto K., Okada T., Mizukami H., Matsushita T., Hanazono Y., Kume A., Nagatsu T., Ozawa K., Nakano I. Neuroprotective effects of glial cell line-derived neurotrophic factor mediated by an adeno-associated virus vector in a transgenic animal model of amyotrophic lateral sclerosis. Journal of Neuroscience 2002, 22:6920-6928.
62. Xu L., Yan J., Chen D., Welsh A.M., Hazel T., Johe K., Hatfield G., Koliatsos V.E. Human neural stem cell grafts ameliorate motor neuron disease in SOD-1 transgenic rats. Transplantation 2006, 82:865-875.
63. Zhang H., Yang B., Mu X., Ahmed S.S., Su Q., He R., Wang H., Mueller C., Sena-Esteves M., Brown R., Xu Z., Gao G. Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system. Molecular Therapy: The Journal of the American Society of Gene Therapy 2011, 19:1440-1448.